A Study to Assess the Management of Febrile Neutropenia in Oncology Patients in a Tertiary Care Hospital

Dr. Finciya C. Pappu¹, Dr. Helna Shaji¹, Dr. Steffi Bennis², Dr. Soumya Mary Alex³, Dr. C. S. Madhu³

¹Department of Pharmacy Practice, St. Joseph’s College of Pharmacy, Cherthala, India
²Department of Oncology, Lourdes Hospital, Ernakulam, India

DOI: 10.36344/sjmps.2022.v08i07.005 | Received: 21.05.2022 | Accepted: 29.06.2022 | Published: 15.07.2022

*Corresponding author: Soumya Mary Alex
Department of Pharmacy Practice, St. Joseph’s College of Pharmacy, Cherthala, India

Abstract

Background: The cytotoxic chemotherapy is the mainstay treatment of cancer and it is usually complicated with infections. Appropriate antibiotics and other supportive medications must be started immediately as bacterial infections may progress with the absence of granulocytes. Improved outcomes can be seen with empirical administration of broad-spectrum antibiotics and they remain as the standard of care. Patients with intermediate-risk for Febrile Neutropenia (FN) (10%-20%) need to be evaluated for additional patient risk factors, after assessment, patients who present with at least one of the risk factors for FN is recommended for treatment with a G-CSF. Methodology: Our study was a retrospective cohort single centered observational study carried out randomly in 104 patients in the oncology department of Lourdes hospital, Cochin Data of the patients were collected from Mediware system, medical records and Statistical software SPSS were used for analysis of the data. Results: In our study febrile neutropenia was managed using antimicrobials, of which antibiotics and antifungals prescribed were 12.09% and 1.97% respectively and with granulocyte-colony stimulating factors (G-CSFs) (6.15%). Principally used empirical monotherapy was meropenem sulbactum / meropenem (n = 48) which was followed by piperacillin tazobactum (n=18) and cefoperazone sulbactum (n=15) This study had a leading prescription of Cyclophosphamid containing chemotherapy regimens which led to neutropenia. Breast cancer patients accounts the majority of febrile neutropenic episodes despite of receiving GCSF prophylaxis. The most common type of cancer patients who are suffering from neutropenia were breast cancer. The compliance with National Comprehensive Cancer Network (NCCN) guidelines were analyzed in that we can see 84.6% patients had partial compliance and 14.4% patients had full compliance. Conclusion: A total of 66 patients received both antibiotics and G-CSF treatment however 13 patients and 25 patients were managed only with G-CSF and antibiotic therapy respectively. This study had a leading prescription of Cyclophosphamide containing chemotherapy regimens which led to neutropenia. These regimes were used mainly in breast cancer patients. Breast cancer patients accounts the majority of febrile neutropic episodes despite of receiving GCSF prophylaxis. The most common type of cancer patients who are suffering from neutropenia were breast cancer. The NCCN guidelines, majority of patients showed partial compliance(86.6%) and about (14.4%) showed full compliance.

Keywords: Febrile neutropenia, National comprehensive cancer network, chemotherapy induced nausea and vomiting, granulocyte colony stimulating factor, absolute neutrophil count, multi drug resistant bacteria.

INTRODUCTION

Febrile neutropenia is one of the most common complications of chemotherapy regimens. Neutropenia is defined as an absolute neutrophil count (ANC) of less than 500 or 1000 cells /mm³ reducing to less than 500 cells /mm³ in a period of 48 hrs. If neutropenic patient develops fever (≥38.3°C or ≥38°C for at least 1 hr), then it is termed as febrile neutropenia (FN). The cytotoxic chemotherapy mediated febrile neutropenia is a serious obstacle for the treatment of cancer patients with a high risk of morbidity and mortality [1, 2]. It is an emergency that leads to an extended hospital stay and high medical cost or even results in the dose reductions or holdback of chemotherapy [3-5]. Neutrophils have an inevitable role in the immune system to eliminate the pathogen directly by releasing cytokines and attacking bacteria or fungal hyphae at the site of infection [6]. In patients with neutropenia, sepsis is a common complication. Among them, gram-negative and gram-positive infections are about 50% case. Mortality is increased in febrile neutropenia especially with bacteraemia [7]. Due to deteriorated immune response fever is the first and foremost sign of infection. It should be identified and managed timely to prevent the progression to severe sepsis and death [8].

The risk factors for the development of febrile neutropenia depends on several factors such as duration of chemotherapy, degree of chemotherapy-induced...
Neutropenia, age, comorbidity, and serum albumin levels [9]. Myelosuppressive chemotherapy affects the neutrophils which is an important component in the immune system thereby rendering the patient immunocompromised. Thus, the neutropenic patients remain susceptible to infections from all varieties of microbes comprising bacteria, fungi, and virus [9, 8, 1]. Most promptly, the patients enduring myelosuppression/ immunosuppressive therapy such as haematology and hematopoietic stem cell transplant (HSCT) are at high risk of febrile neutropenia. In this 13-60% of patient who receives HSCT grew bloodstream infections [10]. Patients should be evaluated as, low to high-risk patients according to the chemotherapeutic regimen which he/she receives [11]. Secondary to the manufacture of recent pharmaceuticals and with the use of systemic chemotherapy, chemotherapy services for both solid and liquid malignancies have drastically expanded. This has improved patient remission and cure rates. Long term and increasing use of chemotherapeutic agents are the reason for the incidence of chemotherapy-induced adverse drug reactions [12].

Neutropenia related infections are the commonest cause of death for cancer patients. Thus, Cancer patients with neutropenic fever must receive broad-spectrum antibiotics to prevent life-threatening complications [13]. The administration of IV empirical antibiotic remains the cornerstone in the initial management of febrile neutropenia. It improves patient survival and prevents death due to infection [14]. The timely commencement of empirical antibiotic is of utmost importance in the initiation of therapy [14, 8]. The monotherapy with broad-spectrum antibiotics is usually followed. The use of granulocyte colony stimulating factors (G-CSF) provides better outcomes in the prevention of neutropenia. This reduces the risk of neutropenic infections and thereby prevent patients from getting nosocomial infections due to intermittent hospital admissions, thus avoiding allied medical costs [15, 4].

Although some guidelines exist for the management of febrile neutropenia, the adherence to it is usually less. The main reason for this non-adherence is the fluctuating patterns of infections, causative agents and the anti-microbial resistance developed by them. Thus, the clinicians rely on the individualised treatment to provide optimal patient care. A variety of multi-drug resistant bacteria (MDR) is emerging nowadays. As a result, the likely pathogens and resistance patterns predominant in the institutions must be studied before initiating empirical antibiotic therapy [16, 8, 5]. The NCCN (National Comprehensive Cancer Network) guidelines recommend the quick initiation of empirical antibiotics after taking the blood cultures within 60 minutes of presentation of fever from neutropenia. The broad-spectrum iv antibiotics like Cefepime, Imipenem, Meropenem or Piperacillin Tazobactam can be used as empirical monotherapy as per the guideline. The empirical Vancomycin therapy is advocated if the gram-positive bacteria is suspected in conditions like iv catheter-related infections and soft tissue infections etc. The complete blood count (CBC) with differential analysis, liver function tests, renal function tests (BUN, Sr. Cr) and electrolytes must be monitored [17, 2].

The only recommendations for neutropenic cancer patients with, 100 neutrophils/µL for 7days are antimicrobials and antifungals. colony-stimulating factors (CSF’s) can be recommended as primary prophylaxis for febrile neutropenia in oncology patients. The use of empirical antibiotic therapy and prevention by CSF’s has reduced the risk and complications of febrile neutropenia [18]. The granulocyte colony stimulating factors (G-CSF) prophylaxis provides hematopoietic recovery preventing chemotherapy-induced neutropenia. This is achieved using granulocyte colony stimulating factors (G-CSF) for the proper duration of days depending on the undergoing chemotherapy [19]. The NCCN guidelines necessitate the use of granulocyte colony stimulating factors (G-CSF) prophylaxis for the patients receiving > 20% FN risk chemotherapy regimens. They do not recommend granulocyte colony stimulating factors (G-CSF) prophylaxis for chemotherapy regimens with < 20% neutropenia risk unless accompanied by any risk factors like elderly, poor performance status, compromised renal or hepatic function, previous therapy for cancer or any presenting infections or neutropenia [20, 3, 4, 15]. However, non-adherence to these guidelines were observed in some studies [20, 19]. The objective of this study is to analyse the prescription patterns of antimicrobials used and to check whether the treatment shows compliance with the NCCN guidelines for the management of febrile neutropenia. This study also evaluates the percentage of neutropenia with the chemotherapies provided and assess the type of cancer more prone to neutropenia.

METHODS

A retrospective single-centre observational study was conducted for a period of 6 months in the oncology department of Lourdes hospital, Cochin. It is a tertiary care multispeciality hospital with 500 beds. Patients were selected randomly from Lourdes Mediware system and medical records from 2016 January to 2020 January. Patients of all age groups on chemotherapy and diagnosed with Febrile neutropenia were included and those who are discharged against medical advice and with incomplete data were excluded from the study. A total of 104 patients were included in the study by calculating sample size. The data were collected using specially designed data collection form. Pertinent laboratory, as well as treatment details were extracted from Lourdes Mediware system and medical record. Statistical analysis was done using SPSS software, graphs and tabulation using Microsoft excel.
**RESULTS**

**Demographic Details**

Among cancer patients hospitalised with Febrile Neutropenia between 2016 January and 2020 January at Lourdes hospital Ernakulam, 104 cases were randomly selected and conducted a retrospective observational study. The mean age of patients was 55.84 years (SD ±10.53 years) with 65 (62.5%) female and 39 (37.5%) males. Figure 1 depicts the distribution of female and male patients in the sample population according to their age category. The mean duration of hospital stay was 6.2 days. The mean body temperature was 38.09°C range.

![Figure 1: Distribution of subjects based on Age Category and Gender](image)

Febrile neutropenia is most common in Solid tumours, among them Breast cancers is more 28 (26.9%) followed by ovarian cancer 10 (9.6%). Non-Hodgkin lymphoma about 15 (14.4%) in Haematological Malignancies are also common in our study.

Table 1 and Figure 2 indicates the distribution of types of cancer among the febrile neutropenic patients in oncology taken in our study. Five (3 female and 2 male) patients were expired during the hospital stay. The Absolute Nuetrophil count of three of them were below 50. Two patients having breast cancer and one each with ovarian cancer, lung cancer, and pancreatic cancer.

| Solid Tumors (83.65%) | N= 87 | Hematological Malignancies (16.35%) | N= 17 |
|-----------------------|-------|-----------------------------------|-------|
| Breast Cancer (32.3%) | 28    | Non Hodgkins                      | 15    |
| Ovarian Cancer (11.6%)| 10    | Lymphoma (88.3%)                  |       |
| Colon Cancer (10.4%)  | 9     | Myelodysplastic                    | 1     |
| Rectum Cancer (6.9%)  | 6     | Syndrome (5.8%)                   |       |
| Lung Cancer (6.9%)    | 6     | Multiple Myeloid                   | 1     |
| Esophageal Cancer (4.6%)| 4  | Leukemia (5.8%)                   |       |
| Endometrium Cancer (4.6%)| 4 |                               |       |
| Pancreas Cancer (4.6%) | 4   |                                   |       |
| Hypopharynx Cancer (4.6%)| 4 |                                   |       |
| Liver Cancer (2.3%)   | 2     |                                   |       |
| Prostrate Cancer (2.3%)| 2  |                                   |       |
| Stomach Cancer (2.3%) | 2     |                                   |       |
| Squamous Cell Cancer (1.1%)| 1 |                                   |       |
| Atypical Extraskeletal Erwigs | 1 |                                   |       |
| Sarcoma (1.1%)        | 1     |                                   |       |
| Malignant Round Cell  | 1     |                                   |       |
| Neoplasam (1.1%)      | 1     |                                   |       |
| Ampullary Tumor (1.1%)| 1   |                                   |       |
| Disseminated Carcinoma| 1   |                                   |       |
| Appendix (1.1%)       | 1     |                                   |       |
| Multiple Germ Cell Tumor (1.1%) | 1 |                                   |       |
The mean ANC was 279.88 cells/ mm$^3$. About 19 (18.3%) patients have ANC less than 100 cells/ mm$^3$, 36 (34.6%) patients had ANC ranging from 100-300 cells/ mm$^3$ and 49 (47.1%) patients ranging from 300-500 cells/mm$^3$. Table 2 depicts the distribution of sample population according to their Absolute Neutrophil Count and age category (ANC).

Table 2: Distribution of subjects based on absolute neutrophil count (ANC)

| Age Category | ANC Category | Total N |
|--------------|--------------|---------|
|              | <100 | 100-300 | 300-500 |       |
| <40          | 2    | 2       | 6       | 10    |
| 40-65        | 13   | 29      | 36      | 78    |
| >65          | 4    | 5       | 7       | 16    |
| TOTAL        | 19   | 36      | 49      | 104   |

Prescribing Pattern of Drugs used in febrile neutropenia Management and all other drugs used

The results were tabulated using Microsoft Excel and Microsoft Word. A total 1364 drugs were prescribed in these patients including those prescribed during hospital stay and discharge. The prescription patterns of all drugs were differentiated and tabulated based on the frequency of their distribution in males and females as given in Figure 3.
In our study febrile neutropenia was managed using antimicrobials, of which antibiotics and antifungals prescribed were 12.09% and 1.97% respectively and with granulocyte-colony stimulating factors (G-CSFs) (6.15%). Table 3 indicates the drugs used in our department for the management of febrile neutropenia.

Table 3: Prescribing pattern of drugs used in febrile neutropenia

| Drugs Used                | Frequency | Total |
|---------------------------|-----------|-------|
| Antibiotics              |           |       |
| Cephalosporins           | 24 Female | 16 Male | 40 Total |
| Cefoperazone Sulbactum   | 12        | 4      | 15 Total |
| Cefepime Tazobactum      | 0         | 2      | 2 Total  |
| Cefpodoxime              | 1         | 0      | 1 Total  |
| Cefotaxime               | 1         | 1      | 2 Total  |
| Cefuroxime               | 3         | 4      | 7 Total  |
| Cefepime                 | 2         | 1      | 3 Total  |
| Cefixime                 | 5         | 4      | 9 Total  |
| Carbapenem               | 44        | 24     | 68 Total |
| Meropenem Sulbactum      | 28        | 15     | 43 Total |
| Meropenem                | 6         | 5      | 11 Total |
| Imipenem                 | 1         | 0      | 1 Total  |
| Faropenem                | 9         | 4      | 13 Total |
| Aminoglycosides          | 2         | 2      | 4 Total  |
| Tobramycin               | 1         | 1      | 2 Total  |
| Amikacin                 | 1         | 2      | 3 Total  |
| Fluoroquinolones         | 7         | 6      | 13 Total |
| Ciprofloxacin Tinidazole | 2         | 2      | 4 Total  |
| Ciprofloxacin            | 3         | 0      | 3 Total  |
| Levofloxacin             | 0         | 1      | 1 Total  |
| Ofloxacin                | 2         | 3      | 5 Total  |
| Penicillins              | 17        | 10     | 27 Total |
| Amoxicillin Clavulanate  | 4         | 2      | 6 Total  |
| Crystalline Penicillin   | 0         | 1      | 1 Total  |
| Piperacillin Tazobactum  | 13        | 7      | 20 Total |
| Others                   | 6         | 7      | 13 Total |
| Metronidazole            | 0         | 2      | 2 Total  |
Drugs Used  | Frequency | Total
---|---|---
**Antibiotics** | | |
Vancomycin | 0 | 1 | 1
Colistin | 2 | 0 | 2
Nitrofurantoin | 1 | 1 | 2
Sulfamethoxazole/Trimethoprim | 1 | 1 | 2
Rifamycin | 0 | 1 | 1
Tinidazole | 1 | 0 | 1
Linezolid | 1 | 1 | 2
**Antifungals** | | |
Flucanazole | 18 | 8 | 26
Clotrimazole | 1 | 0 | 1
G-CSF | 57 | 27 | 84
Filgrastim | 56 | 27 | 83
Pegfilgrastim | 1 | 0 | 1

The antibiotic classes often prescribed in our study population follows the order of Carbapenems (41.20%), Cephalosporins (24.24%), Penicillins (16.36%), Fluoroquinolones (7.89%), Aminoglycosides (3.03%) and others (7.9%) which includes metronidazole, vancomycin, colistin, nitrofurantoin, sulfamethoxazole/trimethoprim, rifamycin, tinidazole and linezolid as plotted in Figure 4.

**Figure 4: Distribution pattern of antibiotics**

Antibiotics such as linezolid, metronidazole, nitrofurantoin and SMX-TMP were included in group others. Various antibiotic regimens used were mentioned in Table 4.

**Table 4: Empirically used antibiotic regimens**

| Empirical Antibiotic Regimen | Number of Patients |
|---|---|
| Meropenem Sulbactum / Meropenem | 48 |
| Piperacillin Tazobactum | 18 |
| Cefoperazone Sulbactum | 15 |
| Cefepime Tazobactum | 2 |
| Amoxicillin Clavulanate | 2 |
| Cefixime | 3 |
| Cefuroxime + Meropenem Sulbactum | 1 |
| Meropenem + Vancomycin | 1 |
| Piperacillin Tazobactum + Amikacin | 4 |
| Piperacillin Tazobactum + Smx/Tmp | 1 |
| Cefotaxime + Metronidazole + Tobramycin | 1 |
| Meropenem/Imipenem + Ciprofloxacin + Tinidazole | 2 |
| Cefoperazone+ Meropenem | 3 |

Principally used empirical monotherapy was Carbapenem, meropenem sulbactum/ meropenem (n = 48) which was followed by piperacillin tazobactum (n=18) and cefoperazone sulbactum (n=15) and the rest was stated in table 4. Empirical dual (n=5) as well as triple therapy (n=8) was also observed. All the empirical antimicrobial therapy were initiated in intravenous route. A total of 66 patients received both carbapenem and an additional agent.
antibiotics and G-CSF treatment however 13 patients and 25 patients were managed only with G-CSF and antibiotic therapy respectively. Table 5 shows the pattern of use of G-CSF and antibiotic prophylaxis among patients based on their ANC values. Empirical antibiotics were used alone in patients mostly (n=13) falling in an ANC category of 300-500 cells/mm3 as is observed with G-CSF monotherapy (n=8).

Inj.Filgrastim 300mcg was the G-CSF of choice in our department and one patient was treated with Inj.Pegfilgrastim. Antifungal prophylaxis with Inj.Fluconazole was observed in 26 patients. Only one female patient was prescribed with Tab.Itraconazole.

| Treatment of FN | ANC Category | G-CSF | Empirical Antibiotic | G-CSF + Empirical Antibiotic |
|-----------------|--------------|-------|-----------------------|-------------------------------|
|                 | <1000        | 1     | 1                     | 17                            |
|                 | 100-300      | 4     | 11                    | 28                            |
|                 | 300-500      | 8     | 13                    | 21                            |
| TOTAL(n)        |              | 13    | 25                    | 66                            |

Table 6: Percentage of febrile neutropenia with each chemotherapy drug

| Chemotherapy Agent | Number of patients (104) | Percentage (%) | Chemotherapy Agent | Number Of patients | Percentage (%) |
|--------------------|--------------------------|----------------|--------------------|--------------------|----------------|
| Cyclophosphamide   | 36                       | 34.61          | Gemcitabine        | 7                  | 6.73           |
| Doxorubicin        | 31                       | 29.80          | Cisplatin          | 7                  | 6.73           |
| Carboplatin        | 21                       | 20.19          | Irinotecan         | 7                  | 6.73           |
| Capecitabine       | 14                       | 13.46          | Paclitaxel         | 5                  | 4.80           |
| Docetaxel          | 14                       | 13.46          | Prednimose         | 4                  | 3.84           |
| 5FU                | 13                       | 12.5           | Cetuximab          | 3                  | 2.88           |
| Vincristine        | 13                       | 12.5           | Bendamustine       | 2                  | 1.92           |
| Calcium Leucovorin | 12                       | 11.53          | Eribulin           | 2                  | 1.92           |
| Oxaliplatin        | 10                       | 9.61           | Trastuzumab        | 2                  | 1.92           |
| Rituximab          | 10                       | 9.61           | Mitoxanthrone      | 2                  | 1.92           |
| Etoposide          | 9                        | 8.65           | Others             | 12                 | 0.96           |
| Bevacizumab        | 8                        | 7.69           |                    |                    |                |

Thus, we assume that Cyclophosphamide had contributed largely to febrile neutropenia occurrence. Cyclophosphamide with Doxorubicin were prescribed in 11 breast cancer patients which was followed by Cyclophosphamide and Docetaxel combination among 10 breast cancer patients. The next leading chemotherapy containing regimen was found in Non Hodgkins Lymphoma treatment (n=6). The cytotoxic chemotherapy regimens that are observed chiefly in our sample population was given in Table 7 with their corresponding ANC values.

Table 7: Distribution of chemotherapy regimen of most commonly administered regimens with anc category

| Chemotherapy Regimen | <1000 | 100-300 | 300-500 | Total | Type Of Cancer         |
|----------------------|-------|---------|---------|-------|------------------------|
| 1. Inj.Cyclophosphamide, Inj.Doxorubicin | 2     | 3       | 6       | 11    | Breast                 |
| 2. Inj.Cyclophosphamide, Inj.Docetaxel   | 1     | 5       | 4       | 10    | BREAST                 |
| 3. Inj.ETOPOSIDE, Inj.CARBOPLATIN        | 2     | 3       | 2       | 7     | Lung, Pancrea S, Prostrate, Breast |
| 4. Inj.Rituximab, Inj.Cyclophosphamide, Inj.Vincristine, Inj.Doxorubicin | 2     | 3      | 1      | 6     | NHL                    |
| 5. Inj.Paclitaxel, Inj.Carboplatin       | 0     | 1       | 3       | 4     | Breast, Ovary, Esophagus |

The most common type of cancer patients who are suffering from neutropenia were breast cancer (n=28).
Patient compliance with NCCN guidelines

Table 8: NCCN guideline compliance

| Guideline standard                                                                 | n  | %   |
|------------------------------------------------------------------------------------|----|-----|
| 1. Full compliance with guideline                                                   | 14.4% |
| 2. Partial compliance with guideline                                                | 84.6% |
| 3. Empirical antibiotics given within 1 hour                                        | 80(77%) |
| 4. Other antibiotics given other than empirical antibiotics (Acc. to NCCN guideline) | 19(18%) |
| 5. Culture done                                                                     | 19(18%) |
| 6. Patients with positive culture                                                   | 11(10.5%) |
| 7. G-CSF drug given                                                                 | 78 (75%) |
| 8. Patients with Complete Blood Count done                                          | 102(98%) |
| 9. Patients with Complete Metabolic Panel done                                      | 78 (75%) |

In this we can see 84.6% patients had partial compliance and 14.4% patients had full compliance with the NCCN guidelines from 104 patients analyzed in our study (Table 11). Empirical antibiotics were given to the patients admitted in the oncology department within 1 hour (n=80) about 77% patients and other antibiotics administered in patients which was recommended by NCCN guidelines were (n=19) 17.7% which helped the patients improve their disease state and health condition. G-csf drugs (n=78) 75% were also given along with these antibiotics. Cultures were done in patients who had persisting infection and high ESR values (n=19) 18.2% of patients, where patients with positive culture was n=11(10.5%). The lab parameters which included complete blood count (n=102) 98% and complete metabolic panel (n=78) 75% were also done in these patients.

Association of antibiotic alone and antibiotic and filgrastim combination with length of stay.

Table 9: t-test on Antibiotics and combination of Antibiotics and Filgrastim

| Treatment                  | N   | Mean    | Std. Deviation | Mean difference | Df  | t value | P value |
|----------------------------|-----|---------|----------------|-----------------|-----|---------|---------|
| Length of hospital stay    |     |         |                |                 |     |         |         |
| Antibiotic only            | 23  | 6.6522  | 5.40714        | 0.07917         | 88  | 0.070   | 0.944   |
| Filgrastim + Antibiotics   | 67  | 6.7313  | 4.40586        |                 |     | 0.063   |         |

The mean length of stay of patients in our study was found to be 6.2308 (SD±4.55) (Table 9). The t-test conducted showed no significant association between patients taking antibiotics and those taking combination of antibiotics and filgrastim with their length of stay with p value of 0.944 (p≤0.5).

DISCUSSION

Our study is a retrospective observational study which aimed at analysing the prescription pattern of all drugs in particular those used in the management of febrile neutropenia and thus help in comparison for further studies. The study also determines the type of cancer and chemotherapy drug which largely contributed to low absolute neutrophil count (ANC) by taking into account the percentage of neutropenia with each chemotherapy agent. The prescription pattern studies similar to our study has not been done before because in our study we reviewed all the drugs prescribed in the prescriptions of 104 febrile neutropenic patients, selected randomly.

Number of patients in the age category 40-65 were predominantly higher than the other age categories. As in our studies, this study also has highest number of patients with age group of 50 to 65 years [21].

Types of cancer:

The most common type of cancer seen in our sample populations were Solid tumors 87(83.65%). Among them breast cancer 28 (32.3%), and ovarian cancer 10 (11.6%). Schelenz S et al conducted a similar study in 2012 where the most common patient groups were with Breast cancer in that study as well, Ovarian cancer was in third place which is analogous to our study followed by oesophageal cancer [22].

Patients taken in our study was categorised according to Absolute Neutrophil Count (ANC) and age category. Out of 104 sample populations, 19 patients have ANC value below 100 cells/mm³. Among them 2 patients were under the age group less than 40 years, 13 patients were aged between 40-65 years and 4 patients were having age above 50 years. 36 patients have ANC value between 100-300 cells/mm³ and ANC category between 300-400 cells/mm³ have 49 patients.

In our prescription patterns the gastrointestinal (GI) agents ranked high accounting for about 20.46% Antimicrobial prophylaxis and G-CSF prophylaxis remains mainstay in the management of FN. Either antibiotic therapy or G-CSF therapy was used alone in patients with ANC count above 300 cells/mm3. Both
treatments were received together in 29 patients with ANC values 100 to 300 cells/mm³ however 17 patients with profound neutropenia received more than one antibiotic therapy along with G-CSF therapy. The therapy may vary with patients performance status, severity of infection, comorbidities and stage of cancer. Febrile neutropenia was also managed with antifungal agents. Antiviral prescriptions were not observed. All the patients were initiated empirical antibiotics therapy intravenously. A greater number of patients were treated with empirical monotherapy with meropenem whereas in a study by K. A. Al. Balushi et al., Empirical dual therapy with Piperacillin tazobactum and Gentamycin (n=82) were paramount followed by Meropenem/Imipenem monotherapy. Besides monotherapy and dual therapy, triple therapy was ordered less frequently [23]. In a similar UK survey study empirical dual therapy with Piperacillin tazobactum and Gentamycin was major (50.4% of oncology units) but only few patients in this setting were prescribed with this dual therapy [24]. Carbapenem monotherapy showed higher success rates which is also evident from metaanalytic study by Xiuge Tang et al. [25]. Most of the patients had their fever resolved – days after initiation of empirical monotherapy. Antifungal prophylaxis with Inj.Filgrastim was predominantly practiced in our centre. In other similar studies antifungal prophylaxis with Amphotericin B was observed [23, 24, 26].

G-CSF prophylaxis is necessary in patients undergoing chemotherapy to prevent neutropenia. Inj.Filgrastim was the one common in use. The use of G-CSF in treatment of neutropenia has now become a routine clinical practice even though NCCN guidelines recommend only its prophylactic use [27, 28].

Among 104 patients a total of 244 chemotherapy drugs were prescribed before the development of neutropenia symptoms. From this, we assumed that Cyclophosphamide (34.61%) is the drug that most causes febrile neutropenia. Other chemotherapeutic agents also contributed to the development of febrile neutropenia. We also assumed that the most common type of cancer patients suffering from febrile neutropenia was with breast cancer (n=28) followed by Non-Hodgkin lymphoma (n=15), Ovarian cancer (n=10).

In a similar study conducted by et al Yosunori et al on 2009-2011. Paclitaxel was their contributing chemotherapeutic regimen for the increase of febrile neutropenia followed by Docetaxel, Cyclophosphamide, Nedaplatin, Doxorubicin, and Carboplatin. Just like in our study the most common type of cancer suffering from neutropenia was breast cancer [29].

Cyclophosphamide and doxorubicin combination regimen had contributed to neutropenia producing ANC values in the range of 300-500 cells/mm³ prominently. Only few patients had profound neutropenia less than 100 cells/mm³.

Patients with temperature of ≥38°C and neutrophil count <500 cells/mm³ are considered as a patient with febrile neutropenia according to the NCCN (National cancer comprehensive network) guidelines. The patients were then checked for history of prior infections as some patients may acquire febrile neutropenia (FN) episodes more than once and also the time since last chemotherapy is checked for possible correlation with the episode of febrile neutropenia. Other factors such as exposure to other patients with tuberculosis, travelling, pets, Blood administration etc. are checked.

The complete blood count (CBC) was taken in 102 patients, showing how rationally the treatment was initiated after the count results. The ANC values were further calculated with an average mean of 279.8 cells/mm³ which indicated for the use of antibiotics and in case of persisting fever antipyretics were provided, most prominently Paracetamol. The lab values were repeated the following days and in cases where respiratory symptoms continued bronchodilators and chest x-ray were done [30].

In our study 10% patients chest x-ray was done. In patients with ESR values elevated and persisting infection cultures were done. As the infection subsides the switch over therapy is initiated where the IV to oral therapy was given and thus lower risk medications were administered instead of broad spectrum of antibiotics along with other supportive care medications. After the antibiotic course of treatment in the hospital, the treatment is completed with the course of antibiotic during discharge upto 5-7 days. The appropriate completion of antibiotics is necessary to avoid resistance.

Initial monitoring of serum creatinine (75%), serum electrolytes (75%) and LFT’s (comprehensive metabolic panel) reduced the risk in patients [30, 31]. The abnormalities had a negative impact on the patient outcome. Thus, they are immediately corrected by supplementation of electrolytes.

In patients with persistent fever and infection culture reports were required to rule out sepsis and sepsis related complications which are disseminated intravascular coagulation, multiple organ failure etc [31,32]. The positive culture reports were seen in 10.5% of patients. The cultures of the organisms isolated were Candida albicans (0.9%), E.Coli (1.9%), Enterococci (1.9%), Grampositive cocci (1.9%), Klebsiella pneumoniae (1.9%) and MRSA (0.9%) which was further treated with culture sensitive antibiotics in aiming of eradicating the organism and providing the patient with clinical cure. The gram
positive organism to be treated with Vancomycin, Linezolid or Daptomycin as per the NCCN guidelines. Here 0.9% of patients each were treated with Vancomycin and Linezolid. In majority of the patients if culture sensitive and if the drug had coverage, Meropenem and Piperacillin Tazobactam were most preferred and other patients were given cephalosporins in for reducing the infection, increasing the ANC count and to eradicate the organism [31].

The patients with no culture (81%) was done were given empirical therapy accordingly to the NCCN guidelines which helped the patients recover completely from the disease state and further patient condition was improved following complete compliance to the treatment. Some patients had chemotherapy along with the febrile neutropenia treatment as the counts improved the chemotherapy was started while monitoring of lab parameters [32]. The delay in chemotherapy could lead to clash in due dates of the patients chemotherapy cycle. The clinicians make sure the patient’s health condition is not compromised and appropriate supplementation is provided to maintain health of the patient.

The response of the therapy is daily evaluated through vital signs, lab parameters, and symptoms of the patient, cultures and X-ray done. The G-CSF (Granulocyte colony stimulating factor) were provided in (n=78) 75% of patients where the patients count could be increased [33]. The patients were rationally treated with compliance to the NCCN guidelines through which the procedures and treatment provided were exactly supporting to the patients therapeutic outcome.

Association of patients taking antibiotics and combination of antibiotics and filgrastim with their length of stay was not significant in our study according to the t-test analysis done. This shows that administering antibiotic alone or filgrastim and antibiotic combination did not affect their clinical outcome with length of stay. In a study by Regis et al the median of length of stay in their study was found to be 16 days [34]. 69% of patients were admitted for more than 10 days. There were patients admitted for 22 days with febrile neutropenia taking intensive therapy. Most patients had invasive fungal infections and blood stream infections which led to increased length of stay. Several factors may have contributed to this insignificant association such as patient’s comorbidities, age, insurance claim and performance status.

CONCLUSION

Febrile Neutropenia is a commonly found in patients receiving certain chemo regimens. Our study concluded that prescription pattern of febrile neutropenia management includes antimicrobials accompanied by gastrointestinal agents to prevent stress ulcers, supplements to boost the immunity, GCF to accelerate recovery, antipyretics to treat fever. Cardiovascular agents, Antidiabetics, Antiasthmatics, Steroids, anticonvulsants etc. were prescribed in patients with comorbidities. This study had a leading prescription of Cyclophosphamide containing chemotherapy regimens which led to neutropenia. These regimens were used mainly in breast cancer patients. Breast cancer patients accounts the majority of febrile neutropenic episodes despite of receiving GCSF prophylaxis. However various risk factors like age, sex, comorbidities, stage of cancer and dose intensity can contribute to neutropenia. The NCCN guidelines are put forward to maintain an appropriate treatment pattern and accurate therapeutic outcome. The patients in our study was treated by the recommendations from NCCN guidelines, majority of patients showed partial compliance (86.6%) and about (14.4%) showed full compliance.

ACKNOWLEDGEMENTS

We are grateful to our Faculties, Oncologist, Nursing staffs, College management and Hospital management for the sincere support, guidance and facilities.

Declaration of Conflict of Interests

The author(s) declared no potential conflicts of interests with respect to the research, authorship and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

Ethical Consideration

We had ethical clearance from Institutional ethics committee of Lourdes Hospital post graduate institute and research centre, Ernakulam.

REFERENCE

1. Al Balushi, K. A., Balkharia, A., Ali, B. H., & Al Rawas, N. (2013). Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos University Hospital, Oman. Journal of infection and public health, 6(3), 216-221.
2. Goldsmith, C., Kalis, J., & Jeffers, K. D. (2018). Assessment of initial febrile neutropenia management in hospitalized cancer patients at a community cancer center. Journal of the advanced practitioner in oncology, 9(6), 659-664.
3. Dulisse, B., Li, X., Gayle, J. A., Barron, R. L., Ernst, F. R., Rothman, K. J., ... & Kaye, J. A. (2013). A retrospective study of the clinical and economic burden during hospitalizations among
cancer patients with febrile neutropenia. *Journal of medical economics*, 16(6), 720-735.
4. Barnes, G., Pathak, A., & Schwartzberg, L. (2014). G-CSF utilization rate and prescribing patterns in the United States: associations between physician and patient factors and GCSF use. *Cancer Medicine*, 3(6), 1477-1484.
5. Wright, J. D., Neugut, A. I., Ananth, C. V., Lewin, S. N., Wilde, E. T., Lu, Y. S., ..., & Hershman, D. L. (2013). Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. *JAMA internal medicine*, 173(7), 559-568.
6. Zimmer, A. J., & Freifeld, A. G. (2019). Optimal management of neutropenic fever in patients with cancer. *Journal of oncology practice*, 15(1), 19-24.
7. Klastersky, J., Ameye, L., Maertens, J., Georgala, A., Muanza, F., Aoun, M., ..., & Paesmans, M. (2007). Bacteremia in febrile neutropenic cancer patients. *International journal of antimicrobial agents*, 30, 51-59.
8. Sipsas, N. V., Bodey, G. P., & Kontoyiannis, D. P. (2005). Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 103(6), 1103-1113.
9. Talcott, J. A., Siegel, R. D., Finberg, R., & Goldman, L. (1992). Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. *Journal of Clinical Oncology*, 10(2), 316-322.
10. Averbuch, D., Orasch, C., Cordonnier, C., Livermore, D. M., Mikulski, M., Viscoli, C., ..., & Akova, M. (2013). European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. *haematologica*, 98(12), 1826-1835.
11. Goodman, L. M., Estfan, B., Montero, A., Kunaparedy, G., Lau, J., Gallagher, E., ..., & Stevenson, J. (2017). Improving the management of patients with low-risk neutropenic fever at the Cleveland Clinic Taussig Cancer Institute. *Journal of Oncology Practice*, 13(3), e259-e265.
12. Sammut, S. J., & Mazhar, D. (2012). Management of febrile neutropenia in an acute oncology service. *QJM: An International Journal of Medicine*, 105(4), 327-336.
13. Freifeld, A., Marchigiani, D., Walsh, T., Chanock, S., Lewis, L., Hiemenz, J., ..., & Pizzo, P. A. (1999). A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. *New England Journal of Medicine*, 341(5), 305-311.
14. Doyle, S. J., Mackson, J. H., & Salter, M. D. (2019). Retrospective Study Of The Management Of Suspected Febrile Neutropenia In A Single-Centre Metropolitan Western Sydney Hospital. *Clinical Audit*, 11, 37-43.
15. Kim, C. G., Sohn, J., Chon, H., Kim, J. H., Heo, S. J., Cho, H., ..., & Kim, G. M. (2016). Incidence of febrile neutropenia in Korean female breast cancer patients receiving preoperative or postoperative doxorubicin/cyclophosphamide followed by docetaxel chemotherapy. *Journal of breast cancer*, 19(1), 76-82.
16. Lam, P. T., Chan, K. S., Tse, C. Y., & Leung, M. W. (2005). Retrospective analysis of antibiotic use and survival in advanced cancer patients with infections. *Journal of pain and symptom management*, 30(6), 536-543.
17. Baden, L. R., Swaminathan, S., Angarone, M., Blouin, G., Camins, B. C., Casper, C., ..., & Smith, C. (2016). Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 14(7), 882-913.
18. Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., ..., & Ramsey, S. D. (2013). Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*, 31(6), 794-810.
19. Morrison, V. A., Wong, M., Hershman, D., Campos, L. T., Ding, B., & Malin, J. (2007). Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. *Journal of Managed Care Pharmacy*, 13(4), 337-348.
20. Klastersky, J., Paesmans, M., Aoun, M., Georgala, A., Loizidou, A., Lalami, Y., ..., & Dal Lago, L. (2016). Clinical research in febrile neutropenia in cancer patients: past achievements and perspectives for the future. *World Journal of Clinical Infectious Diseases*, 6(3).
21. Okera, M., Chan, S., Dermede, U., Larkin, J., Popat, S., Gilbert, D., ..., & Chowdhury, S. (2011). A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCPEOD findings. *British journal of cancer*, 104(3), 407-412.
22. Schelenz, S., Giles, D., & Abdallah, S. (2012). Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. *Annals of oncology*, 23(7), 1889-1893.
23. Al Balushi, K. A., Balkhair, A., Ali, B. H., & Al Rawas, N. (2013). Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos University
Hospital, Oman. *Journal of infection and public health*, 6(3), 216-221.

24. Ziglam, H. M., Gelly, K., & Olver, W. (2007). A survey of the management of neutropenic fever in oncology units in the UK. *International journal of antimicrobial agents*, 29(4), 430-433.

25. Tang, X., Chen, L., Li, Y., Jiang, J., Li, X., & Liang, X. (2020). Carbapenems versus alternative β-lactams monotherapy or in combination for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trial. *Medicine*, 99(43), e22725.

26. Choi, S. M., Park, S. H., Lee, D. G., Choi, J. H., Yoo, J. H., & Shin, W. S. (2008). Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey. *Journal of Korean medical science*, 23(6), 941-947.

27. Roy, V., Saxena, D., Agarwal, M., Bahadur, A. K., & Mishra, B. (2010). Use of antimicrobial agents and granulocyte colony stimulating factors for febrile neutropenia in cancer patients in a tertiary care hospital in India. *Indian Journal of Cancer*, 47(4), 430-436.

28. Wright, J. D., Neugut, A. I., Ananth, C. V., Lewin, S. N., Wilde, E. T., Lu, Y. S., ... & Hershman, D. L. (2013). Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. *JAMA internal medicine*, 173(7), 559-568.

29. Hashiguchi, Y., Kasai, M., Fukuda, T., Ichimura, T., Yasui, T., & Sumi, T. (2015). Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. *Anti-Cancer Drugs*, 26(10).

30. Khanna, R., Alva Venur, V., Narechania, S., Elson, P., Daw, H., Spiro, T. P., & Haddad, A. (2016). Prophylactic use of Granulocyte-colony stimulating factors (G-CSF) in cancer patients: Adherence to NCCN guidelines.

31. Lal, A., Bhurgri, Y., Rizvi, N., Virwani, M., Memon, R. U., Saeed, W., ... & Khurshid, M. (2008). Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. *Asian Pacific journal of cancer prevention: APJCP*, 9(2), 303.

32. Shaikh, A. J., Bawany, S. A., Masood, N., Khan, A. A., Abbasi, A. N., Niamutullah, S. N., ... & Kumar, S. (2011). Incidence and impact of baseline electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. *Journal of Cancer*, 2, 62.

33. Raymond, E., Boige, V., Faire, S., Sanderink, G. J., Rixe, O., Vermillet, L., ... & Armand, J. P. (2002). Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. *Journal of clinical oncology*, 20(21), 4303-4312.

34. Rosa, R. G., & Goldani, L. Z. (2014). Factors associated with hospital length of stay among cancer patients with febrile neutropenia. *PLoS One*, 9(10), e108969.